
## Ales Zak

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3208698/publications.pdf Version: 2024-02-01



ALES ZAK

#	Article	IF	CITATIONS
1	Novel biochemical markers for non-invasive detection of pancreatic cancer. Neoplasma, 2022, 69, 474-483.	1.6	5
2	FADS Polymorphisms Affect the Clinical and Biochemical Phenotypes of Metabolic Syndrome. Metabolites, 2022, 12, 568.	2.9	1
3	Altered Indices of Fatty Acid Elongases ELOVL6, ELOVL5, and ELOVL2 Activities in Patients with Impaired Fasting Glycemia. Metabolic Syndrome and Related Disorders, 2021, 19, 386-392.	1.3	3
4	A Matched Case-Control Study of Noncholesterol Sterols and Fatty Acids in Chronic Hemodialysis Patients. Metabolites, 2021, 11, 774.	2.9	2
5	Associations of Serum Uric Acid with Endogenous Cholesterol Synthesis Indices in Men with High Cardiometabolic Risk. Metabolic Syndrome and Related Disorders, 2020, 18, 212-218.	1.3	0
6	Diagnostic criteria for the determination of clinically significant internal carotid artery stenosis using duplex ultrasound. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2020, 164, 255-260.	0.6	4
7	Dyslipidemia in patients with chronic kidney disease: etiology and management. Vnitrni Lekarstvi, 2020, 66, 275-281.	0.2	6
8	Comprehensive sterol and fatty acid analysis in nineteen nuts, seeds, and kernel. SN Applied Sciences, 2019, 1, 1.	2.9	23
9	Fish oil supplementation with various lipid emulsions suppresses in vitro cytokine release in home parenteral nutrition patients: a crossover study. Nutrition Research, 2019, 72, 70-79.	2.9	5
10	Polymeric bile acid sequestrants: Review of design, inÂvitro binding activities, and hypocholesterolemic effects. European Journal of Medicinal Chemistry, 2018, 144, 300-317.	5.5	27
11	Lipid Metabolism in Patients with End-Stage Renal Disease: A Five Year Follow-up Study. Current Vascular Pharmacology, 2018, 16, 298-305.	1.7	3
12	Plasma Phospholipid Fatty Acid Profile is Altered in Both Septic and Non‧eptic Critically III: A Correlation with Inflammatory Markers and Albumin. Lipids, 2017, 52, 245-254.	1.7	17
13	Polymorphisms of SCD-1 gene, increased oxidative stress and insulin resistance in persons with elevated concentrations of apolipoprotein B48. Atherosclerosis, 2017, 263, e66.	0.8	0
14	ls lipoprotein subfraction analysis in patients in chronic hemodialysis reasonable? - a pilot study. Atherosclerosis, 2017, 263, e274.	0.8	0
15	Fatty Acid Composition of Plasma Phosphatidylcholine Determines Body Fat Parameters in Subjects with Metabolic Syndrome-Related Traits. Metabolic Syndrome and Related Disorders, 2017, 15, 371-378.	1.3	5
16	Plasma Phosphatidylcholines Fatty Acids in Men with Squamous Cell Esophageal Cancer: Chemoradiotherapy Improves Abnormal Profile. Medical Science Monitor, 2016, 22, 4092-4099.	1.1	8
17	Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis. Cancer Biomarkers, 2016, 17, 55-65.	1.7	21
18	Chronic pancreatitis and the composition of plasma phosphatidylcholine fatty acids. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016, 108, 38-44.	2.2	11

Ales Zak

#	Article	IF	CITATIONS
19	The Synthesis and Characterization of the Poly[ <i>N</i> â€vinylpyrrolidoneâ€ <i>co</i> â€ethylideneâ€bisâ€3â€( <i>N</i> â€vinylâ€2â€pyrrolidone)] Hydroge for Drug Delivery to the Gastrointestinal Tract. Macromolecular Symposia, 2016, 366, 14-22.	l <mark>Ma</mark> trix	1
20	Pleiotropic effects of niacin: Current possibilities for its clinical use. Acta Pharmaceutica, 2016, 66, 449-469.	2.0	21
21	Increased inflammatory markers with altered antioxidant status persist after clinical recovery from severe sepsis: a correlation with low HDL cholesterol and albumin. Clinical and Experimental Medicine, 2016, 16, 557-569.	3.6	33
22	Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?. Medical Science Monitor, 2015, 21, 2156-2162.	1.1	24
23	The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 442-448.	0.6	10
24	Xanthomas: Clinical and pathophysiological relations. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2014, 158, 181-188.	0.6	121
25	Omega-3 phospholipids from fish suppress hepatic steatosis by integrated inhibition of biosynthetic pathways in dietary obese mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2014, 1841, 267-278.	2.4	69
26	Altered Activities of Antioxidant Enzymes in Patients with Metabolic Syndrome. Obesity Facts, 2013, 6, 39-47.	3.4	41
27	Relationship between serum bilirubin and uric acid to oxidative stress markers in Italian and Czech populations. Journal of Applied Biomedicine, 2013, 11, 209-221.	1.7	9
28	Antioxidant Status and Oxidative Stress Markers in Pancreatic Cancer and Chronic Pancreatitis. Pancreas, 2013, 42, 614-621.	1.1	70
29	Fatty acid composition of commercially available nutrition supplements. Czech Journal of Food Sciences, 2013, 31, 241-248.	1.2	11
30	Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumor Biology, 2012, 33, 1695-1700.	1.8	41
31	Plasma Fatty Acid Composition in Patients with Pancreatic Cancer: Correlations to Clinical Parameters. Nutrition and Cancer, 2012, 64, 946-955.	2.0	43
32	Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Medical Science Monitor, 2012, 18, CR512-CR517.	1.1	24
33	Improvements in colorectal cancer screening programmes - quantitative immunochemical faecal occult blood testing - how to set the cut-off for a particular population. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 143-150.	0.6	6
34	Statin use and serum bilirubin levels. Atherosclerosis, 2011, 219, 969.	0.8	5
35	Leptin and adiponectin in pancreatic cancer: connection with diabetes mellitus. Neoplasma, 2011, 58, 58-64.	1.6	30
36	FATTY ACIDS AS BIOCOMPOUNDS: THEIR ROLE IN HUMAN METABOLISM, HEALTH AND DISEASE - A REVIEW. PART 1: CLASSIFICATION, DIETARY SOURCES AND BIOLOGICAL FUNCTIONS. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2011, 155, 117-130.	0.6	252

Ales Zak

#	Article	IF	CITATIONS
37	FATTY ACIDS AS BIOCOMPOUNDS: THEIR ROLE IN HUMAN METABOLISM, HEALTH AND DISEASE - A REVIEW. PART 2: FATTY ACID PHYSIOLOGICAL ROLES AND APPLICATIONS IN HUMAN HEALTH AND DISEASE. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2011, 155, 195-218.	0.6	139
38	Decreased paraoxonase activity in critically ill patients with sepsis. Clinical and Experimental Medicine, 2010, 10, 21-25.	3.6	75
39	Soluble receptor for advanced glycation end-products (sRAGE) and polymorphisms of RAGE and glyoxalase I genes in patients with pancreas cancer. Clinical Biochemistry, 2010, 43, 882-886.	1.9	47
40	Antioxidative enzymes and increased oxidative stress in depressive women. Clinical Biochemistry, 2009, 42, 1368-1374.	1.9	162
41	Fatty Acid CoA Ligase-4 Gene Polymorphism Influences Fatty Acid Metabolism in Metabolic Syndrome, but not in Depression. Tohoku Journal of Experimental Medicine, 2009, 217, 287-293.	1.2	17
42	Polymorphism -23HPhI in the promoter of insulin gene and pancreatic cancer: A pilot study. Neoplasma, 2009, 56, 26-32.	1.6	16
43	The influence of polymorphism of â^'493G/T MTP gene promoter and metabolic syndrome on lipids, fatty acids and oxidative stress. Journal of Nutritional Biochemistry, 2008, 19, 634-641.	4.2	18
44	PLASMA HOMOCYSTEINE AND INDICES OF AN OXIDATIVE STRESS IN DEPRESSIVE DISORDER. Atherosclerosis Supplements, 2008, 9, 257.	1.2	0
45	Severity of Metabolic Syndrome Unfavorably Influences Oxidative Stress and Fatty Acid Metabolism in Men. Tohoku Journal of Experimental Medicine, 2007, 212, 359-371.	1.2	27
46	Resting energy expenditure and thermal balance during isothermic and thermoneutral haemodialysis heat production does not explain increased body temperature during haemodialysis. Nephrology Dialysis Transplantation, 2007, 22, 3553-3560.	0.7	16
47	A genomically/chemically complete module for synthesis of lipid membrane in a minimal cell. Biotechnology and Bioengineering, 2007, 97, 397-409.	3.3	15
48	Mo-P6:448 Fatty acid binding protein 2 gene polymorphisms: Connection with plasma and VLDL triglyceride levels. Atherosclerosis Supplements, 2006, 7, 144-145.	1.2	0
49	N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin–fibrate combination. Journal of Nutritional Biochemistry, 2006, 17, 379-384.	4.2	55
50	Hypolipidemic Drugs Can Change the Composition of Rat Brain Lipids. Tohoku Journal of Experimental Medicine, 2004, 204, 299-308.	1.2	15
51	Higher Content of 18:1 Trans Fatty Acids in Subcutaneous Fat of Persons with Coronarographically Documented Atherosclerosis of the Coronary Arteries. Annals of Nutrition and Metabolism, 2003, 47, 302-305.	1.9	12
52	Assessment of dietary and genetic factors influencing serum and adipose fatty acid composition in obese female identical twins. Lipids, 2002, 37, 27-32.	1.7	45
53	Effect of column and software on gas chromatographic determination of fatty acids. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 770, 91-99.	2.3	6
54	Analysis of fatty acids in plasma lipoproteins by gas chromatography–flame ionization detection. Analytica Chimica Acta, 2002, 465, 337-350.	5.4	66

ALES ZAK

#	Article	IF	CITATIONS
55	The Responses of Serum and Adipose Fatty Acids to a Oneâ€Year Weight Reduction Regimen in Female Obese Monozygotic Twins. Annals of the New York Academy of Sciences, 2002, 967, 311-323.	3.8	20
56	Treatment of Hypertriglyceridemia with Fenofibrate, Fatty Acid Composition of Plasma and LDL, and Their Relations to Parameters of Lipoperoxidation of LDL. Annals of the New York Academy of Sciences, 2002, 967, 336-341.	3.8	6
57	Effects of Selected Anthropometric Parameters on Plasma Lipoproteins, Fatty Acid Composition, and Lipoperoxidation. Annals of the New York Academy of Sciences, 2002, 967, 522-527.	3.8	1
58	Significance of fat distribution for VLDL and LDL composition and parameters of lipoperoxidation. Atherosclerosis, 1999, 144, 62.	0.8	0
59	Relationships of insulinaemia and obesity to fatty acid composition and parameters of lipoperoxidation of VLDL and LDL. Atherosclerosis, 1999, 144, 62.	0.8	Ο
60	Chromium levels in patients with internal diseases. IUBMB Life, 1998, 46, 365-374.	3.4	15
61	4.P.108 Glucose tolerance and fatty acid composition of the major plasma lipid classes in hyperlipoproteinemic patients. Atherosclerosis, 1997, 134, 318.	0.8	0
62	4.P.71 Effect of aminoguanidine and vitamin E treatment on the oxidative modification of lipoproteins in diabetic rats. Atherosclerosis, 1997, 134, 310-311.	0.8	0
63	Relationships between Fatty Acid Composition and Insulin?induced Oxidizability of Low?Density Lipoproteins in Healthy Men. Annals of the New York Academy of Sciences, 1997, 827, 269-278.	3.8	2
64	Increased Lipoprotein Oxidability and Aortic Lipid Peroxidation in an Experimental Model of Insulin Resistance Syndrome. Annals of the New York Academy of Sciences, 1997, 827, 521-525.	3.8	12
65	Effect of 4-wk treatment of obesity by very-low-calorie diet on anthropometric, metabolic, and hormonal indexes. American Journal of Clinical Nutrition, 1992, 56, 281S-282S.	4.7	16
66	Effects of dietary n-3 fatty acids on the composition of cholesteryl esters and triglycerides in plasma and liver perfusate of the rat. Journal of Nutritional Biochemistry, 1990, 1, 472-477.	4.2	1
67	Elevation of High Density Lipoproteins in Acromegalics after Lisuride Treatment. Hormone and Metabolic Research, 1985, 17, 220-221.	1.5	8
68	Gas Chromatographic Study of Cholesterol Esterification during Postheparin Lipolysis in Vitro in Hypertriglyceridemia. Scandinavian Journal of Clinical and Laboratory Investigation, 1978, 38, 134-137.	1.2	14